Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 22;109(2):119-126.
doi: 10.1136/heartjnl-2022-321492.

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank

Zahra Raisi-Estabragh  1   2 , Jackie Cooper  3 , Ahmed Salih  3 , Betty Raman  4 , Aaron Mark Lee  3 , Stefan Neubauer  4 , Nicholas C Harvey  5   6 , Steffen E Petersen  3   2   7   8
Affiliations

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank

Zahra Raisi-Estabragh et al. Heart. .

Abstract

Objective: To examine association of COVID-19 with incident cardiovascular events in 17 871 UK Biobank cases between March 2020 and 2021.

Methods: COVID-19 cases were defined using health record linkage. Each case was propensity score-matched to two uninfected controls on age, sex, deprivation, body mass index, ethnicity, diabetes, prevalent ischaemic heart disease (IHD), smoking, hypertension and high cholesterol. We included the following incident outcomes: myocardial infarction, stroke, heart failure, atrial fibrillation, venous thromboembolism (VTE), pericarditis, all-cause death, cardiovascular death, IHD death. Cox proportional hazards regression was used to estimate associations of COVID-19 with each outcome over an average of 141 days (range 32-395) of prospective follow-up.

Results: Non-hospitalised cases (n=14 304) had increased risk of incident VTE (HR 2.74 (95% CI 1.38 to 5.45), p=0.004) and death (HR 10.23 (95% CI 7.63 to 13.70), p<0.0001). Individuals with primary COVID-19 hospitalisation (n=2701) had increased risk of all outcomes considered. The largest effect sizes were with VTE (HR 27.6 (95% CI 14.5 to 52.3); p<0.0001), heart failure (HR 21.6 (95% CI 10.9 to 42.9); p<0.0001) and stroke (HR 17.5 (95% CI 5.26 to 57.9); p<0.0001). Those hospitalised with COVID-19 as a secondary diagnosis (n=866) had similarly increased cardiovascular risk. The associated risks were greatest in the first 30 days after infection but remained higher than controls even after this period.

Conclusions: Individuals hospitalised with COVID-19 have increased risk of incident cardiovascular events across a range of disease and mortality outcomes. The risk of most events is highest in the early postinfection period. Individuals not requiring hospitalisation have increased risk of VTE, but not of other cardiovascular-specific outcomes.

Keywords: COVID-19; epidemiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SEP provides consultancy to Cardiovascular Imaging, Calgary, Alberta, Canada. BR has consulted for Axcella Therapeutics. The remaining authors have nothing to disclose.

Figures

Figure 1
Figure 1
Flow chart of participant selection.
Figure 2
Figure 2
Summary of study design and results. AF, atrial fibrillation; CVD, cardiovascular disease; IHD, ischaemic heart disease; MI, myocardial infarction; VTE, venous thromboembolism. Red bars indicate statistically significant associations (p<0.05).
Figure 3
Figure 3
Histograms of event time for all incident outcomes. Blue bars represent incident events in COVID-19 cases, while the red bars indicate those in matched controls. AF, atrial fibrillation; CVD, cardiovascular disease; HF, heart failure; IHD, ischaemic heart disease; MI, myocardial infarction; VTE, venous thromboembolism.
See this image and copyright information in PMC

Comment in

Similar articles

  • Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer.
    Raisi-Estabragh Z, Cooper J, McCracken C, Crosbie EJ, Walter FM, Manisty CH, Robson J, Mamas MA, Harvey NC, Neubauer S, Petersen SE. Raisi-Estabragh Z, et al. Heart. 2023 Jun 14;109(13):1007-1015. doi: 10.1136/heartjnl-2022-321888. Heart. 2023. PMID: 37072241 Free PMC article.
  • Cardiovascular Risk Factors Associated With Venous Thromboembolism.
    Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, Burgess S, Bell S, Sweeting M, Rimm EB, Kabrhel C, Zöller B, Assmann G, Gudnason V, Folsom AR, Arndt V, Fletcher A, Norman PE, Nordestgaard BG, Kitamura A, Mahmoodi BK, Whincup PH, Knuiman M, Salomaa V, Meisinger C, Koenig W, Kavousi M, Völzke H, Cooper JA, Ninomiya T, Casiglia E, Rodriguez B, Ben-Shlomo Y, Després JP, Simons L, Barrett-Connor E, Björkelund C, Notdurfter M, Kromhout D, Price J, Sutherland SE, Sundström J, Kauhanen J, Gallacher J, Beulens JWJ, Dankner R, Cooper C, Giampaoli S, Deen JF, Gómez de la Cámara A, Kuller LH, Rosengren A, Svensson PJ, Nagel D, Crespo CJ, Brenner H, Albertorio-Diaz JR, Atkins R, Brunner EJ, Shipley M, Njølstad I, Lawlor DA, van der Schouw YT, Selmer RM, Trevisan M, Verschuren WMM, Greenland P, Wassertheil-Smoller S, Lowe GDO, Wood AM, Butterworth AS, Thompson SG, Danesh J, Di Angelantonio E, Meade T; Emerging Risk Factors Collaboration. Gregson J, et al. JAMA Cardiol. 2019 Feb 1;4(2):163-173. doi: 10.1001/jamacardio.2018.4537. JAMA Cardiol. 2019. PMID: 30649175 Free PMC article.
  • Lifestyle trajectories and ischaemic heart diseases: a prospective cohort study in UK Biobank.
    Gao Y, Chen Y, Hu M, Song J, Zhang Z, Sun H, Wang J, Lin Y, Wu IXY. Gao Y, et al. Eur J Prev Cardiol. 2023 Mar 27;30(5):393-403. doi: 10.1093/eurjpc/zwad001. Eur J Prev Cardiol. 2023. PMID: 36602532
  • Incident Clinical and Mortality Associations of Myocardial Native T1 in the UK Biobank.
    Raisi-Estabragh Z, McCracken C, Hann E, Condurache DG, Harvey NC, Munroe PB, Ferreira VM, Neubauer S, Piechnik SK, Petersen SE. Raisi-Estabragh Z, et al. JACC Cardiovasc Imaging. 2023 Apr;16(4):450-460. doi: 10.1016/j.jcmg.2022.06.011. Epub 2022 Sep 14. JACC Cardiovasc Imaging. 2023. PMID: 36648036 Free PMC article.
  • Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.
    Schmucker C, Eisele-Metzger A, Meerpohl JJ, Lehane C, Kuellenberg de Gaudry D, Lohner S, Schwingshackl L. Schmucker C, et al. Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2. Cochrane Database Syst Rev. 2022. PMID: 35199850 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. . Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021;398:599–607. 10.1016/S0140-6736(21)00896-5 - DOI - PMC - PubMed
    1. Daugherty SE, Guo Y, Heath K, et al. . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2021;373:n1098. 10.1136/bmj.n1098 - DOI - PMC - PubMed
    1. Xie Y, Xu E, Bowe B, et al. . Long-term cardiovascular outcomes of COVID-19. Nat Med 2022;28:583–90. 10.1038/s41591-022-01689-3 - DOI - PMC - PubMed
    1. UK Biobank Coordinating Centre . UK Biobank: protocol for a large-scale prospective epidemiological resource. UKBB-PROT-09-06 (main phase), 2007. https://www.ukbiobank.ac.uk/media/gnkeyh2q/study-rationale.pdf
    1. Armstrong J, Rudkin JK, Allen N, et al. . Dynamic linkage of COVID-19 test results between Public Health England’s second generation surveillance system and UK Biobank. Microb Genomics 2020;6:mgen000397. 10.1099/mgen.0.000397 - DOI - PMC - PubMed

Publication types

MeSH terms